CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the appointment of Donna Grogan, M.D. to its Board of Directors.
“We are excited to have Dr. Grogan join our Board. She has led numerous investigational new drug applications and marketing authorization applications, and has extensive experience with international regulatory authorities,” said Craig Wheeler, President and Chief Executive Officer at Momenta Pharmaceuticals. “We look forward to her input as we advance multiple candidates in our pipeline.”
“I am honored to join Momenta’s Board of Directors as the team makes strides in addressing the needs of patients with rare autoimmune diseases,” adds Dr. Donna Grogan. “With potentially transformative therapies in the pipeline, I look forward to the opportunity to work closely with the Momenta team to optimize the value of the company’s therapeutics.”
Dr. Grogan recently stepped down as the Chief Medical Officer of Clementia Pharmaceuticals (acquired by Ipsen in April 2019) and is a board-certified internal medicine physician with 15 years of experience in clinical medicine. Prior to working at Clementia, Dr. Grogan served as the Chief Medical Officer for several Health Care Venture focused companies including Anexon, Apofore, and DecImmune. She previously worked at FoldRx Pharmaceuticals (acquired by Pfizer October 2010) as Chief Medical Officer. She has been involved with multiple high-profile product approvals including Lunesta®, Xopenex HFA®, Brovana™ and most recently the EMA authorization of Vyndaqel® (tafamidis) for the treatment of the rare neurologic disease Transthyretin Familial Amyloid Polyneuropathy. Dr. Grogan received her Bachelor of Arts degree from College of the Holy Cross and a Doctorate from University of Illinois College of Medicine, III.
Momenta Pharmaceuticals is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases and advancing its late stage biosimilar portfolio. The company is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
The Company’s logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the use efficacy, safety, tolerability, convenience and commercial potential of our product candidates. Forward-looking statements may be identified by words such as "believe," "continue," “plan to”, "potential," "will," and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including the risk of the unpredictable nature of early stage development efforts for our product candidates; safety, efficacy or tolerability problems with our product candidates; unexpected adverse clinical trial results; and those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Momenta Pharmaceuticals, Inc.